|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7584 USD | +8.87% |
|
-4.44% | -90.23% |
| 06-30 | OneMedNet Corporation announced that it expects to receive $25 million in funding | CI |
| 06-29 | OneMedNet Corporation(NasdaqCM:ONMD) added to Russell Microcap Value Benchmark Index | CI |
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -279.79 | -338.72 | -33.88 | -286.48 | -205.58 | |
Return on Total Capital | 317.11 | 530.59 | -73.13 | 77.29 | 141.13 | |
Return On Equity % | 68.69 | 80.21 | 1.29K | 68.92 | 29.62 | |
Return on Common Equity | 68.68 | 80.21 | 1.29K | 68.92 | 29.62 | |
Margin Analysis | ||||||
Gross Profit Margin % | -10.39 | -31.29 | -12.52 | -43.7 | -37.01 | |
SG&A Margin | 179.01 | 416.64 | 647.46 | 1.22K | 562.84 | |
EBITDA Margin % | -246.95 | -528.43 | -816.94 | -1.48K | -706.55 | |
EBITA Margin % | -248.27 | -530.58 | -819.68 | -1.49K | -711.33 | |
EBIT Margin % | -248.27 | -530.58 | -819.68 | -1.49K | -711.33 | |
Income From Continuing Operations Margin % | -269.36 | -569.63 | -2.27K | -1.58K | -206.11 | |
Net Income Margin % | -269.36 | -569.63 | -2.27K | -1.58K | -206.11 | |
Net Avail. For Common Margin % | -269.36 | -569.63 | -2.27K | -1.58K | -206.11 | |
Normalized Net Income Margin | -168.35 | -356.02 | -777 | -984.35 | -383 | |
Levered Free Cash Flow Margin | -68.67 | -301.65 | 2.83K | 1.12K | -576.95 | |
Unlevered Free Cash Flow Margin | -57.48 | -279.78 | 2.88K | 1.13K | -573.87 | |
Asset Turnover | ||||||
Asset Turnover | 1.8 | 1.02 | 0.07 | 0.31 | 0.46 | |
Fixed Assets Turnover | 25.97 | 17.35 | 11.23 | 6.21 | 16.57 | |
Receivables Turnover (Average Receivables) | 7.61 | 20.82 | 11.98 | 3.52 | 3.84 | |
Short Term Liquidity | ||||||
Current Ratio | 0.18 | 0.13 | 0.03 | 0.19 | 0.43 | |
Quick Ratio | 0.17 | 0.12 | 0.02 | 0.02 | 0.22 | |
Operating Cash Flow to Current Liabilities | -0.39 | -0.6 | 0.64 | -0.36 | -1.56 | |
Days Sales Outstanding (Average Receivables) | 47.99 | 17.53 | 30.48 | 103.88 | 95.08 | |
Average Days Payable Outstanding | 174.13 | 228.34 | 1.11K | 2.19K | - | |
Long Term Solvency | ||||||
Total Debt/Equity | -85.87 | -94.05 | -39.67 | -54.94 | -32.85 | |
Total Debt / Total Capital | -607.77 | -1.58K | -65.75 | -121.93 | -48.92 | |
LT Debt/Equity | -27.13 | -14.47 | -3.62 | - | -7.42 | |
Long-Term Debt / Total Capital | -191.99 | -243.1 | -5.99 | - | -11.05 | |
Total Liabilities / Total Assets | 745.78 | 876.5 | 2.88K | 527.96 | 237.84 | |
EBIT / Interest Expense | -13.87 | -15.17 | -11.18 | -65.34 | -144.28 | |
EBITDA / Interest Expense | -13.8 | -15.1 | -11.14 | -64.95 | -143.31 | |
(EBITDA - Capex) / Interest Expense | -13.95 | -15.25 | -11.2 | -65.3 | -143.51 | |
Total Debt / EBITDA | -1.82 | -1.65 | -0.61 | -0.92 | -0.1 | |
Net Debt / EBITDA | -1.56 | -1.6 | -0.61 | -0.9 | -0.04 | |
Total Debt / (EBITDA - Capex) | -1.8 | -1.63 | -0.61 | -0.91 | -0.1 | |
Net Debt / (EBITDA - Capex) | -1.54 | -1.59 | -0.6 | -0.89 | -0.04 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 32.49 | 5.58 | -11.37 | -37.02 | 111.35 | |
Gross Profit, 1 Yr. Growth % | -153.4 | 218.05 | -64.54 | 117.83 | 79 | |
EBITDA, 1 Yr. Growth % | -7.61 | 125.93 | -26.79 | 39.9 | 0.57 | |
EBITA, 1 Yr. Growth % | -7.56 | 125.64 | -26.71 | 40.16 | 0.65 | |
EBIT, 1 Yr. Growth % | -7.56 | 125.64 | -26.71 | 40.16 | 0.65 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 4.23 | 123.28 | 272.5 | -70.01 | -72.35 | |
Net Income, 1 Yr. Growth % | 4.23 | 123.28 | 272.5 | -70.01 | -72.35 | |
Normalized Net Income, 1 Yr. Growth % | -3.77 | 123.28 | 71.95 | -70 | -17.76 | |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 111.76 | -27.94 | -92.23 | -82.57 | |
Accounts Receivable, 1 Yr. Growth % | -53.04 | -79.32 | 699.16 | 40.13 | 132.39 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 45.11 | 66.97 | 18.98 | 9.09 | -48.15 | |
Total Assets, 1 Yr. Growth % | 169.3 | 55.6 | -98.48 | 703.23 | -42.29 | |
Tangible Book Value, 1 Yr. Growth % | 99.39 | 87.08 | -238.67 | 18.66 | -81.41 | |
Common Equity, 1 Yr. Growth % | 99.39 | 87.08 | -238.67 | 18.66 | -81.41 | |
Cash From Operations, 1 Yr. Growth % | -13.21 | 220.47 | -90.58 | 45.75 | 7.93 | |
Capital Expenditures, 1 Yr. Growth % | - | 94.2 | -24.73 | 15.91 | -74.51 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | 363.82 | -185.43 | -77.22 | 4.75 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | 413.91 | -187.47 | -76.94 | 5.49 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 18.27 | -3.26 | -25.31 | 15.37 | |
Gross Profit, 2 Yr. CAGR % | - | 30.32 | 6.2 | -11.74 | 97.46 | |
EBITDA, 2 Yr. CAGR % | - | 44.48 | 75.94 | -8.49 | 18.61 | |
EBITA, 2 Yr. CAGR % | - | 44.43 | 75.77 | -8.31 | 18.77 | |
EBIT, 2 Yr. CAGR % | - | 44.43 | 75.77 | -8.31 | 18.77 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 52.55 | 180.9 | 27.51 | -71.2 | |
Net Income, 2 Yr. CAGR % | - | 52.55 | 180.9 | 27.51 | -71.2 | |
Normalized Net Income, 2 Yr. CAGR % | - | 46.58 | 107.82 | 17.09 | -50.33 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 20.32 | -48.61 | -88.37 | |
Accounts Receivable, 2 Yr. CAGR % | - | -68.84 | 28.56 | 235.04 | 80.46 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 55.66 | 40.95 | 14 | -24.79 | |
Total Assets, 2 Yr. CAGR % | - | 104.7 | -27.59 | -65.01 | 115.31 | |
Tangible Book Value, 2 Yr. CAGR % | - | 93.14 | 50.16 | 31.15 | -53.03 | |
Common Equity, 2 Yr. CAGR % | - | 93.14 | 50.16 | 31.15 | -53.03 | |
Cash From Operations, 2 Yr. CAGR % | - | 66.78 | 111.12 | -71.71 | 25.14 | |
Capital Expenditures, 2 Yr. CAGR % | - | - | 20.9 | -6.34 | -45.64 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 521.18 | -53.96 | -50.12 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 584.4 | -53.49 | -50.26 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | 7.43 | -16.18 | 5.64 | |
Gross Profit, 3 Yr. CAGR % | - | - | -15.55 | 35.32 | 11.72 | |
EBITDA, 3 Yr. CAGR % | - | - | 41.95 | 52.43 | -5.56 | |
EBITA, 3 Yr. CAGR % | - | - | 41.88 | 52.46 | -5.42 | |
EBIT, 3 Yr. CAGR % | - | - | 41.88 | 52.46 | -5.42 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 101.85 | 51.02 | -23.39 | |
Net Income, 3 Yr. CAGR % | - | - | 101.85 | 51.02 | -23.39 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 60.78 | 51.01 | 4.08 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -19.05 | -64.16 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | -8.1 | 32.42 | 196.58 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 42.32 | 29.47 | -12.33 | |
Total Assets, 3 Yr. CAGR % | - | - | 12.19 | 61.61 | -58.65 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 65.05 | 40.89 | -31.62 | |
Common Equity, 3 Yr. CAGR % | - | - | 65.05 | 40.89 | -31.62 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 56.98 | 55.86 | -55.86 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 19.43 | -39.3 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 112.34 | -38.59 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 126.27 | -38.55 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 10.52 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 18.82 | |
EBITDA, 5 Yr. CAGR % | - | - | - | - | 26.9 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 26.95 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 26.95 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | -0.15 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | -0.15 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 22.2 | |
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | 20.43 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 10.3 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 45.67 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 0.72 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 0.72 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 28.7 |
- Stock Market
- Stocks
- ONMD Stock
- ONMD Stock
- Financials OneMedNet Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















